[{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ASC41","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"ERX-1000","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral pill","sponsorNew":"RespireRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"RespireRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"TCMCB07","moa":"MC3\/4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Not Applicable"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Janssen Sciences Ireland Unlimited","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"CIN-109","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"CinRx Pharma \/ Janssen Sciences Ireland Unlimited","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Janssen Sciences Ireland Unlimited"},{"orgOrder":0,"company":"Gmax Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"GMA106","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gmax Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gmax Biopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gmax Biopharm \/ Not Applicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Ecnoglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sciwind Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sciwind Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"TCMCB07","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Not Applicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"TCMCB07","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Not Applicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"TCMCB07","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Not Applicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"XW014","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sciwind Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sciwind Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"TCMCB07","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AMG 133","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"ZP8396","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VK2735","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VK2735","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TLC-6740","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"OrsoBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Not Applicable"},{"orgOrder":0,"company":"MindRank","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"MDR-001","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"MindRank","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"MindRank \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MindRank \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"ZP8396","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"DR10624","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zhejiang Doer Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Doer Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"RDX-002","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Response Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Response Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Not Applicable"},{"orgOrder":0,"company":"Eccogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ECC5004","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eccogene","amount2":2.0099999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.0099999999999998,"dosageForm":"Tablet","sponsorNew":"Eccogene \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Eccogene \/ AstraZeneca"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TERN-601","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"CT-388","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Carmot Therapeutics","amount2":3.1000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":3.1000000000000001,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Carmot Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"KER-065","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Apitegromab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Rock \/ Not Applicable"},{"orgOrder":0,"company":"Gubra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"GUB014295","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gubra \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Not Applicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Not Applicable","leadProduct":"RM-718","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rhythm Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"CIN-110","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"CinRx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Not Applicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Oxyntomodulin Analog","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"RDX-002","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Response Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Response Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Metsera","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Metsera","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.28999999999999998,"dosageForm":"Injection","sponsorNew":"Metsera \/ ARCH Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"Metsera \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NNC6022-0001","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Private Placement","leadProduct":"DA-1726","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Exenatide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Vivani Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Not Applicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Private Placement","leadProduct":"DA-1726","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"CIN-109","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"CinRx Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Beacon Biosignals","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Nimacimab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Beacon Biosignals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Beacon Biosignals \/ Skye Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Beacon Biosignals \/ Skye Bioscience"},{"orgOrder":0,"company":"Xeno Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"XEN-101","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Xeno Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Xeno Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeno Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Gubra","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"BI 3034701","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Gubra","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Gubra"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Exenatide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Vivani Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CT-996","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"Cytoki Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"CK-0045","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Cytoki Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Cytoki Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytoki Pharma \/ Not Applicable"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"CIN-110","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"CinRx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Yunovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ID110521156","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Yunovia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Yunovia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Yunovia \/ Not Applicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"TERN-601","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"TLC-6740","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"OrsoBio \/ Ascenta Capital","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Ascenta Capital"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Exenatide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Vivani Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Not Applicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Oxyntomodulin Analog","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Modular Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"GUB014295","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Modular Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Modular Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Modular Medical \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Metsera","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"MET-097","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Amneal Pharmaceuticals \/ Metsera","highestDevelopmentStatusID":"6","companyTruncated":"Amneal Pharmaceuticals \/ Metsera"},{"orgOrder":0,"company":"KeyBioscience","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Expanded Collaboration","leadProduct":"LY3541105","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"KeyBioscience","amount2":1.3999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1.3999999999999999,"dosageForm":"","sponsorNew":"KeyBioscience \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"KeyBioscience \/ Eli Lilly"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Amycretin","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ASC30","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Exenatide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Vivani Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CT-996","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"RES-010","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Resalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Resalis Therapeutics \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Resalis Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Choline Chloride","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Protara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cytoki Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"CK-0045","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Cytoki Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Cytoki Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytoki Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Radella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"MD-18","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Radella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Radella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Radella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Gubra","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"BI 1820237","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Gubra \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Gubra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"GUB014295","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Gubra \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Not Applicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ASC47","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Relmada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Relmada Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"RES-010","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Resalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Resalis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Resalis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"LAE102","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Laekna Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Laekna Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ASC47","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Exenatide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Vivani Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Not Applicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"TCMCB07","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Not Applicable"},{"orgOrder":0,"company":"Verdiva Bio","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"VRB-101","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Verdiva Bio","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Verdiva Bio \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Verdiva Bio \/ Forbion"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Verdiva Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sciwind Biosciences","amount2":2.4700000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.4700000000000002,"dosageForm":"Tablet","sponsorNew":"Sciwind Biosciences \/ Verdiva Bio","highestDevelopmentStatusID":"6","companyTruncated":"Sciwind Biosciences \/ Verdiva Bio"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AMG 513","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"WVE-007","moa":"INHBE","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"BIIB078","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"BIIB078","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"QRL-201","moa":"STMN2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series B Financing","leadProduct":"QRL-201","moa":"STMN2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"QurAlis \/ EQT Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ EQT Life Sciences"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"QRL-201","moa":"STMN2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF beta-1\/COX-2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF beta-1\/COX-2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"QRL-201","moa":"STMN2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-007","moa":"INHBE","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Wave Life Sciences \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : WVE-007 is a GalNAc-conjugated small interfering RNA (siRNA) designed to silence Inhibin βE (INHBE) gene expression, being investigated for treating obesity.

                          Product Name : WVE-007

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          February 06, 2025

                          Lead Product(s) : WVE-007

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : AMG 513 is an injectable medicine being developed by Amgen for the treatment of cardiometabolic diseases like obesity. The mechanism of action is currently undefined.

                          Product Name : AMG 513

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 05, 2025

                          Lead Product(s) : AMG 513

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : ASC30 is the first and only small molecule GLP-1 receptor (GLP-1R) agonist that can be dosed once-monthly subcutaneously and once-daily orally for the treatment of obesity.

                          Product Name : ASC30

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 21, 2025

                          Lead Product(s) : ASC30

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank